Biological are the main suppliers in the domestic market

The industry estimates that from disposable self destruction syringe factory to September 2019, its sales have exceeded 4 billion yuan, and the growth rate has accelerated., the sales of these varieties are still considerable, and the growth momentum is strong, which has contributed more than 1 billion yuan in sales revenue to enterprises.3 billion yuan, an increase of more than 90% year-on-year.482 billion yuan, an increase of more than 150% year-on-year; operating net profit exceeded 1.

According to industry data, the scale of China’s cold medicine market has exceeded 50 billion yuan in 2018, and Chinese patent medicines and chemical medicines each accounted for about half.. According to 2018 PDB data, oseltamivir sales accounted for over 85% of anti-flu and anti-disease drugs.

So, in the high flu season, which pharmaceutical companies are expected to win opportunities? Antiviral drug companies It is understood that common antiviral drugs for influenza treatment are neuraminidase inhibitors. It can be seen that there is still a large market for proprietary Chinese medicine companies. Among them, Kangtai Biological, Zhifei Biological and Watson Biological are the main suppliers in the domestic market,

which are called ’the vaccine three swordsmen’ by the industry. According to the third quarter report of 2019, all three major influenza vaccine companies have achieved rapid performance growth. It can be said that oseltamivir from Dongyang Sunshine has almost monopolized the domestic market. In order to prevent influenza, the National Influenza Prevention and Control Plan (Trial) issued by the National Health and Medical Commission at the end of 2018 proposed five treatment measures, including strengthening epidemic surveillance and research, strengthening the application of influenza vaccine, and strengthening epidemic prevention in key places Control, strengthen the handling of outbreaks, and strengthen medical treatment.

 

0 kommentarer